The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

The EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...

AbbVie says that Elahere is the first and only folate receptor alpha (FRɑ)-directed antibody drug conjugate (ADC) medicine ...

AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

AbbVie (ABBV) announced the European Commission, or EC, granted marketing authorization for Elahere for the treatment of adult patients with ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.